CORRECTION



Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations: A Podcast

Xiuning Le¹ · Eric Nadler² · Daniel B. Costa³ · John Victor Heymach¹

Published online: 9 December 2023 © The Author(s) 2023

Correction to: Targeted Oncology (2023) 18:807–817 https://doi.org/10.1007/s11523-023-00994-2

An Acknowledgment statement was added to this publication:

Acknowledgements Some of the research described in this review was funded in part through National Institutes of Health (NIH)/National Cancer Institute (NCI) grant R37 CA218707 (to DB Costa).

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

The original article can be found online at https://doi.org/10.1007/ $\,$ s11523-023-00994-2.

 [⊠] Xiuning Le xle1@mdanderson.org

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

² Baylor University Medical Center, Dallas, TX, USA

Division of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA